Patent Update: Inhibitors of the Phospholipases A₂

References to primary literature

• CONNOLLY S, ROBINSON DH: Recent advances in phospholipase A2 research. Drug News Perspect. (1993) 6(8) In press.
   Google Scholar
• GLASER KB, MOBILIO D, CHANG JY, SENKO N: Phospholipase A2 enzymes; regulation and inhibition. TIPS (1993) 14(3):92–98.
   PubMed Web of Science ®Google Scholar
• MAYERR J, MARSHALLL A: New insights on mammalian phospholipase A~(s); comparison of arachidonoyl-selective and -nonselective enzymes. FASEB J. (1993) 7(2):339–348.
   Google Scholar
• Three very recent complementary reviews which cover all major aspects of PLA2 research to date. References cited therein address most of the points discussed in the Intro-duction.
   Google Scholar
• JAIN MK, YUAN W, GELB MH: Competitive inhibition of phospholipase A2 in vesicles. Biochemistry (1989) 28(10):4135–4139.
   PubMed Web of Science ®Google Scholar
• BENNION C, CONNOLLY S, GENSMANTEL NP, HALLAM C, JACKSON CG, PRIMROSE WU, ROBERTS GCK, ROBINSON DH, SLAICH PK: Design and synthesis of some substrate ana-logue inhibitors of phospholipase A2 and in-vestigations by NMR and molecular mod-eling into the binding interactions in the enzyme-inhibitor complex. J. Med. Chem. (1992) 35(16):2939–2951.
   Google Scholar
• Contains a description of a dual screening strategy for pancreatic PLA2s which uses 'monomeric' substrate and mixed micelle assay systems.
   Google Scholar
• JAIN MK, ROGERS J, JAHAGIRDAR DV, MARECEK, JF, RAMIREZ F: Kinetics of interfacial cataly-sis by phospholipase A2 in intravesicle scoot-ing mode, and heterofusion of anionic and zwitterionic vesicles. Biochem. Biophys. Acta (1986) 860:435–447.
   Google Scholar
• The first demonstration of PLA2 catalysis in the 'scooting' mode.
   Google Scholar
• PARTEARROYO MA, OSTOLAZA H, GONI FM, BARBERA-GU1LLEM E: Surfactant-induced cell toxicity and cell lysis. Biochem. Pharmacol. (1990) 40(6):1323–1328.
   PubMed Web of Science ®Google Scholar
• FURSTENBERGER G, RICHTER H, FUSENIG NE, MARKS F: Arachidonic acid and PGE2 re-lease and enhanced cell proliferation in-duced by the phorbol ester TPA in a murine epidermal cell line. Cancer Lett. (1981) 11:191–198.
   PubMed Web of Science ®Google Scholar
• GARST ME: Phospholipase A2 inhibitors. Curr Opin. Thera. Patents (1992) 2(4):400–408.
   Google Scholar
• PoTrs BCM, FAULKNER DJ, JACOBS RS: Phospholipase Ay inhibitors from marine or-ganisms. J. Nat. Prod. (1992) 55(12):1701–1717.
   Google Scholar
• A recent review of phospholipase A2 inhibitors (including manoalide) which have been isolated from marine organ-isms.
   Google Scholar
• MARSHALL LA, BOLOGNESE B, YUAN W, GELB M: Phosphonate-phospholipid ana-logues inhibit human phospholipase A2. Agents Actions (1991) 34(1/2):106–109.
   Google Scholar
• BENNETT CF, MONG S, Wu H-LW, CLARK MA, WHEELER L, CROOKE ST Inhibition of phosphoinositide-specific phospholipase C by manoalide. Mol. Pharmacol. (1987) 32(5):587–593.
   PubMed Web of Science ®Google Scholar
• DE VRIES GW, AMDAHL L, MOBASSER A, WENZEL M, WHEELER LA: Preferential inhibition of 5-lipoxygenase activity by manoalide. Biochem. Pharmacol. (1 988) 37:2899-2905
   Google Scholar
• CAUFIELD CE, RINKER JM, VON BURG G, GLASER K, MARSHALL L, SUNG A: Lecture presentation at the 205th. Am. Chem. SOC. Natl. Mtg., Denver, 28 March-2 April 1993, Medi 106. (Con$ Fast-Track New Chem. Entities (1993) 1(2):2).
   Google Scholar
• YOSHIDA T, NAKAMOTO S. SAKAZAKI R, MATSUMOTO K, TERUI Y, SATO T, ARITA H, MATSUTANI S: Thielocins Ala and AO. No-vel phospholipase Ay inhibitors from As-comycetes. J. Antibiotics (1991) 44(12):1467–1470.
   Google Scholar
• KATO T: Thielocin Alp, a novel group II phosholipases A2 inhibitor from fungi. Poster presentation at the 1992 FASEB Summer Con-ference on Phospholipases, July 13–17, Saxtons River, Vermont, USA: Poster No 10.
   Google Scholar
• TANAKA K, KATO T, MATSUMOTO K, YOSHIDA T: Anti-inflammatory action of thielocin A 1 (3, a group II phospholipase Ay inhibitor, in rat carrageenan-induced pleurisy. Inflam-mation (1993) 17(2):107–119.
   PubMed Web of Science ®Google Scholar
• MIYAICE A, YAMAMOTO H, TAKEBAYASHI Y, IMAI H, HONDA K: The novel natural prod-uct YM-26567-1 [(+)-trans-4-(3-dodecanoy1-2,4,6-trihydroxypheny1)-7-hydroxy-2-(4-hydro-xyphenyl)chroman]: A competitive inhibitor of group II phospholipase A2. J. Pharmacol. Exp. Ther. (1992) 263(3):1302–1307.
   PubMed Web of Science ®Google Scholar
• WASHBURN WN, DENNIS EA: Novel gen-eral approach for the assay and inhibition of hydrolytic enzymes utilising suicide-in-hibitory bifunctionally linked substrates (SIB-LINKS): exemplified by a phospholipase A2 assay. J. Am. Chem. Soc. (1990) 112:2040–2041.
   Web of Science ®Google Scholar
• WASHBURN WN, DENNIS EA: Suicide-in-hibitory bifunctionally linked substrates (SIB-LINKS) as phospholipase A2 inhibitors. J. Biol. Chem. (1991) 266(8):5042–5048.
   PubMed Web of Science ®Google Scholar
• TRAMPOSCH KM, STEINER SA, STANLEY PL, NETTLETON DO, FRANSON RC, LEWIN AH, CARROLL FL Novel inhibitor of phospholi-pase A2 with topical anti-inflammatory ac-tivity. Biochem. Biophys. Res. Commun. (1992) 189(1):272–279.
   PubMedGoogle Scholar
• It is not clear which class of enzyme this 68 Id3 protein belongs to. It is interesting to note, however, that in early reports [2O], cPLA2 was believed (incorrectly) to have a molecular weight in the 60/70kD region.
   Google Scholar
• LESLIE CC, VOELICER DR, CHANNON Pr', WALL MM, ZELARNEY PT: Properties and purification of an arachidonoyl-hydrolysing phospholipase A2 from a macrophage cell line, RAW 264.7. Biochem. Biophys. Acta (1988) 963(3):476–492.
   Google Scholar
• GUICHARDANT M, TRAITLER H, SPIELMANN D, SPRECHER H, FINOT P-A: Stearidonic acid, an inhibitor of the 5-lipoxygenase pathway. A comparison with timnodonic acid and dihomogammalinolenic acid. Lipids (1993) 28(4):321–324.
   Google Scholar
• OINUMA H, TAKAMURA T, HASEGAWA T, NOMOTO K-I, NAITOH T, DAIKU Y, HAMAN° S, KAKISAWA H, MiNAmi N: Synthesis and biological evaluation of substituted benzene-sulphonamides as novel potent membrane-bound phospholipase A2 inhibitors. J. Med. Chem. (1991) 34(7):2260–2267.
   PubMed Web of Science ®Google Scholar
• CHANG J, BLAZEK E, CARLSON RP: Inhibitionof phospholipase A2 (PLA2) activity by nifedipine and nisoldipine is independent of their calcium-channel-blocking activity. In-flammation (NY) (1987) 11(3):353–364.
   Google Scholar
• CABRE F, MORENO JJ, CARABAZA A, ORTEGA E, MALTLEON D, CARGANICO G: Antiflammins - Anti-inflammatory activity and effect on human phospholipase A2. Biochem. Pharma-col. (1992) 44(3):519–525.
   Google Scholar
• Includes a short discussion about the controversy sur-rounding the anti-inflammatory activity of the `antiflam-mins'.
   Google Scholar
• PERETTI M, BECHERUCCI C, MUGRIDGE KG, SOLITO E, SILVESTRI S, PARENTE L: A no-vel anti-inflammatory peptide from hu-man lipocortin V. Br. J. Pharmacol. (1991) 103(2):1327–1332.
   PubMed Web of Science ®Google Scholar
• BOMALASKI JS, BAKER DG, BROPHY L, RESURRECCION NV, SPILBERG I, MLTNIAIN M, CLARK MA: A phospholipase A2-activat-ing protein (PLAP) stimulates human neu-trophil aggregation and release of lysosomal enzymes, superoxide, and eicosanoids. J. Im-munol. (1989) 142(10:3957–3962.
   PubMedGoogle Scholar